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Abstract 
Introduction: Different mechanisms for the expression of pendrin which is an apical iodide transporter have been reported in nodular 
thyroid tissues compared to normal thyroid. The aim of the present study was to determine the alterations of pendrin expression in 
nodular and surrounding non-nodular thyroid tissues and clarify the role of pendrin in the functional behaviour of nodular lesions.
Material and methods: Twenty-six nodular and paired non-nodular normal thyroid tissues were collected at the same centre. Patients 
were divided into two groups based on the function of the dominant thyroid nodule; hot nodules (n = 18) and cold nodules (n = 8). 
mRNA levels of pendrin were evaluated by quantitative RT-PCR. Pendrin protein expression was determined by immunohistochemical 
analysis. Results of dominant nodules were compared to non-nodular thyroid tissue of the same patient. 
Results: No statistically significant difference was found with respect to qualitative and quantitative measurements of pendrin expres-
sion between hot and cold nodules. However, percent immunohistochemical staining of pendrin was significantly higher in both hot 
and cold nodules compared to non-nodular thyroid tissue of the same patients. RT-PCR revealed comparable mRNA levels of pendrin 
gene between hot nodules and corresponding normal thyroid tissues. However, in cold nodules, significantly decreased mRNA levels of 
pendrin were observed compared to normal thyroid tissue. mRNA levels of pendrin showed significant positive correlation with TSH in 
corresponding non-nodular thyroid tissues.
Conclusions: The present study demonstrates that expression of pendrin could not be influenced by TSH in thyroid nodules and expres-
sion level of pendrin seems not to have an effect on nodule function. (Endokrynol Pol 2013; 64 (3): 208–214)
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Streszczenie
Wstęp: W guzkowej tkance tarczycowej opisano odmienny od pozaguzkowej tkanki tarczycowej mechanizm ekspresji pendryny — 
transportera jodu zlokalizowanego w części szczytowej komórki. Celem badania było ustalenie zmian w ekspresji pendryny w guzkowej 
tkance tarczycowej i otaczającej ją pozaguzkowej tkance tarczycowej, aby wyjaśnić rolę pendryny w zachowaniu czynnościowym zmian 
guzkowych.
Materiał i metody: W tym samym ośrodku pobrano 26 wycinków guzkowej tkanki tarczycowej i sparowanych wycinków pozaguzkowej 
prawidłowej tkanki tarczycowej. Pacjentów podzielono na dwie grupy w zależności od statusu czynnościowego guzka dominującego: 
grupę z guzkami gorącymi (n = 18) i grupę z guzkami zimnymi (n = 8). Poziom mRNA i pendryny oznaczono ilościowo metodą RT-PCR. 
Ekspresję białka pendryny oznaczono metodą immunohistochemiczną. Wyniki dla guzków dominujących porównano z wynikami dla 
tkanki pozaguzkowej u tego samego pacjenta.
Wyniki: Nie stwierdzono statystycznie znamiennych różnic pomiędzy guzkami gorącymi i zimnymi, jeżeli chodzi o wyniki oznaczenia 
ilościowego i jakościowego ekspresji pendryny. Procentowe barwienie immunohistochemiczne w kierunku pendryny było natomiast 
znamiennie większe zarówno w przypadku guzków gorących, jak i zimnych w porównaniu z tkanką pozaguzkową u tych samych 
pacjentów. RT-PCR wykazało porównywalne poziomy mRNA genu kodującego pendrynę w guzkach gorących i prawidłowej tkance 
tarczycowej u tych samych pacjentów. Z kolei w przypadku guzków zimnych stwierdzono znamiennie niższe poziomy pendryny 
w porównaniu z prawidłową tkanką tarczycową. Stwierdzono też korelację dodatnią poziomu mRNA pendryny i poziomu TSH w ko-
respondujących tkankach pozaguzkowych.
Wnioski: W przeprowadzonym badaniu wykazano, że na ekspresję pendryny nie może mieć wpływu TSH w guzkach tarczycy oraz że 
poziom ekspresji pendryny nie wydaje się wpływać na czynność guzków. (Endokrynol Pol 2013; 64 (3):208–214)
Słowa kluczowe: pendryna, ekspresja, guzki tarczycy
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Introduction
Nodular goitre is a complex disease with a high preva-
lence but its pathogenesis is still not completely 
understood. Both genetic and environmental factors 
have been found to play a role [1–3]. The best known 
environmental factor is iodine deficiency [4]. Ciga-
rette smoking, nutritional goitrogens, and radiation 
exposure are the other known environmental factors. 
Constitutional parameters like age and female gen-
der are also important in the aetiology of nodules. 
Genetic background is a factor in whether all the 
abovementioned environmental factors will cause 
nodule development [1–3].
The development of nodular goitre is thought to 
be a continuous process starting from thyroid hyper-
plasia and simple diffuse goitre. Therefore, genes cod-
ing for thyroglobulin (Tg), thyroid peroxidase (TPO), 
sodium-iodide symporter (NIS) and pendrin, which are 
important proteins in thyroid physiology and hormone 
synthesis, are candidate genes for the development of 
nodular goitre [5–9].
Pendrin is a hydrophobic transmembrane glyco-
protein located at the apical membrane of thyrocytes 
[7, 8, 10, 11]. The gene coding for pendrin known as 
pendred gene (PDS) was cloned in 1997 [12]. It is lo-
cated at chromosome 7q 22-31 and composed of 2,343 
base pairs. PDS (SLC26A4) is a member of an anion 
transporter family known as SCL26A. Besides thyroid, 
PDS is expressed mainly in the inner ear and kidney. 
In the inner ear and kidney, pendrin functions as a Cl/ 
/HCO3 exchanger [13, 14].
Pendrin in the thyroid is thought to be responsible 
for iodide efflux from the follicular epithelium to the fol-
licular lumen where organification of iodide takes place 
[15, 16]. Pendred Syndrome is an autosomal recessive 
disorder caused by mutations in the PDS gene and is 
associated with goitre and sensorineural hearing loss 
[17, 18]. The goitre in Pendred Syndrome is variable in 
its expression. When present, it is often multinodular, 
develops around puberty, and is generally characterised 
by a positive perchlorate discharge test whereby iodide 
is inappropriately discharged from the thyroid upon 
stimulation with perchlorate [18].
Pendrin expression of normal and tumoural thyroid 
tissues has been investigated in various studies [10, 
17, 19, 20]. In the present study, we investigated the 
expression of pendrin in benign nodules and their sur-
rounding normal thyroid tissue samples by both PCR 
and immunohistochemistry. Our aim was to determine 
the differences between the expression level of pendrin 
both in nodular and paired non-nodular thyroid tissue 
and to detect the correlation between pendrin expres-
sion and functional status of the nodule.
Material and methods
This prospective study was designed from Endocrinol-
ogy and Metabolism, Surgery and Pathology Depart-
ment of Istanbul University Faculty of Medicine. Thy-
roid tissue specimens were collected from 52 unrelated 
patients undergoing total or near total thyroidectomy 
for removal of solitary nodule or multinodular goitre. 
All patients were negative for anti-thyroglobulin and 
anti-thyroperoxidase antibodies. Fifteen patients had a 
family history of goitre.
Tissue samples
Tissue specimens of the dominant thyroid nodule and 
surrounding normal-appearing (non-nodular) thyroid 
were collected from each patient at the time of surgery. 
They were frozen in liquid nitrogen and stored at –80oC. 
Detailed information on the nodules of each patient 
was obtained by physical examination, scintigraphy 
and ultrasonography, so that the dominant nodule 
could be identified unequivocally both at the time of 
specimen taking during surgery and at post-operative 
histological examination. Histological examination 
was done by two experienced pathologists at different 
times. Lymphocytic thyroiditis was observed in paired 
non-nodular thyroid tissue of 20 patients and six pa-
tients were found to have papillary carcinoma in the 
dominant nodule. The abovementioned 26 cases were 
excluded from the study. 
Nodules were divided into two groups as hot (n = 18) 
or cold (n = 8) based on the scintigraphic features of 
the dominant nodule. Diagnosis of toxic adenoma 
and toxic multinodular goitre was based on the signs 
and symptoms of thyrotoxicosis, increased serum free 
thyroid hormones and suppressed TSH concentration 
(i.e. TSH ‹ 0.270 mU/mL; lower limit of normal range), 
associated with a nodular goitre presenting predomi-
nant technetium uptake in one (or more) nodule(s) as 
shown by the scintigraphy. The diagnosis of euthyroid 
nodular goitre was made by finding normal TSH (i.e. 
0.27–4.0 IU/mL) in the presence of nodular goitre. Table 
1 summarises the clinical and histological charecteristics 
of the remaining 26 patients. 
Immunohistochemistry
Immunohistochemistry was performed on paraffin-
embedded tissues. Tissue blocks of the 26 patients were 
obtained from the archival material of the Pathology 
Department of Istanbul University, Faculty of Medicine. 
0.5–2 µcm thick sections of the dominant nodule and 
paired non-nodular thyroid tissue were cut and mount-
ed on glass slides, deparaffinised by serial passages 
in xylene and alcohol series. Subsequently, for heat 
antigen retrieval (AR), microwave pretreatment (three 
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cycles of 5 min each) was performed in 10 mM EDTA 
buffer (pH:8). Then endogenous peroxidase activity was 
quenched with % 3H202 for 20 min. Blockade of the 
proteins was done using Large Volume Ultra V Block 
(cat no: TA-015-UB). Sections were subsequently incu-
bated for two hours at RT with the monoclonal Anti-
Pendrin antibody (Clone UIRF, 01065 Code No:KO143) 
diluted at 1/100. After washing with PBS, the sections 
were incubated with biotinylated goat anti-polyvalent 
antibody (Cat no: TP-015-BN) for 25 min at RT and 
washed in PBS again. Following this, incubation with 
streptavidin peroxidase (Cat no: TS-015-HR) for 25 min 
was performed. After washing with PBS, staining was 
completed by incubation with a substrate chromogen 
solution (AEC chromogen; Cat no: TA-015-HAS). Nega-
tive controls were obtained by studying non-thyroid 
tissues and by studying thyroid tissues incubated with 
preimmune antisera and immune sera preabsorbed 
with excess corresponding peptide.
Immunohistochemical evaluation
The number of positive cells was counted in ten micro-
scopic fields at a magnification of x 200. The percentage 
of stained cells in every microscopic field was deter-
mined and then the mean percentage of immunostain-
ing was calculated. This was done for both the dominant 
nodule and the paired non-nodular thyroid tissue of 
each patient. Immunostaining intensity was also taken 
into account in immunohistochemical analysis (grade 
0 = no staining; grade 1 = faint, grade 2 = intermediate 
between 1 and 3; and grade 3 = strong).
Extraction of RNA
Frozen samples of nodules and their paired normal 
thyroid tissue corresponding to those examined in 
immunohistochemical study were analysed for their 
mRNA content. Total RNA was isolated using an RNA 
extraction kit (RNeasy Fibrous Tissue Kit, Qiagen, Ger-
many) according to the manufacturer’s instructions. 
The quality of RNA was assessed by conventional gel 
electrophoresis. Only RNAs showing the clear band 
intensity of 28S and 18S rRNAs were selected for fur-
ther analysis.
Reverse Transcription RT
Complementary DNA (cDNA) was synthesised from 
total RNA. One microgram of total RNA was reverse 
transcribed in a 20-µL reaction volume containing 5 µg/mL 
random hexamers, 0.5 mM dNTP, 0.01 M DTT, 1 U/µL 
ribonuclease inhibitor, 2.5 U/µL reverse transcriptase 
(all enzymes and chemicals were supplied from MBI 
Fermentas, Germany). The thermal cycling for cDNA 
synthesis consisted of 10 min of hybridisation of 
random hexamers and total RNA at 70oC, 1 h of RT 
reaction at 37oC and 5 min of RT-inactivation at 99oC. 
cDNA synthesised by PCR was stored at –20oC prior to 
quantitative PCR analysis.
Real-time Quantitative PCR
Expression levels of pendrin mRNA and the housekeep-
ing gene b2-microglobulin (B2MG) as endogenous con-
trol were analysed by quantitative PCR using LightCy-
cler (Roche Diagnostics GmbH, Germany). We used the 
SYBR Green 1 dye (Roche, Mannheim, Germany) bind-
ing method. Oligonucleotide primers for pendrin and 
(B2MG) as endogenous control were as follows: pendrin 
forward primer, 5’-CGGATATGGTCTCTACTCTGC-3’; 
pendrin reverse primer, 5’-TGCTGCTGGATACGAGA-
AAGTG-3’. B2MG forward primer, 5’-TGC CGT GTG 
AAC CAT GTG AC-3’ and B2MG reverse primer, 5’- ACC 
TCC ATG ATG CTG CTT ACA-3’. 
The following amplification programme was used: 
one cycle of 60 seconds (s) at 95oC, followed by 45 cycles 
consisting of 10 s at 95oC, 5 s at 58oC, and 20 s at 72oC. 
Melting curve analysis consisted of 0 s at 95oC, 10 s at 
65oC, and 10 s at 95oC. A standard run curve was gen-
erated for each amplification using serial dilutions of 
a cDNA mixture expressing the genes analysed. Expres-
sion of each gene was calculated with a programme 
found in LightCycler software. Quantification results 
were expressed in relative expression units [REUs]. 
REUs were calculated using expression of b2-microglob-
ulin as endogenous control. (REU = target gene (pen-
drin) expression/b2-microglobulin expression × 100). 
The protocol of this study was approved by the Ethi-
cal Committee of Istanbul University Medical Faculty. 
Informed consent was obtained from all patients before 
the procedures.
Statistical analysis
Data was entered and analysed by Software Package 
for Social Sciences version 13 [SPSS 13]. Data was ex-
pressed as percentage, frequency; mean ± standard 
deviation [SD]. Expression levels were compared using 
nonparametric Wilcoxon signed-rank test. Correlation 
of pendrin gene expression with clinical parameters 
was analysed using Spearman’s test and p < 0.05 was 
considered statistically significant.
Results
Pendrin Protein Expression
Pendrin protein expression was investigated by immu-
nohistochemistry in all thyroid tissue samples (Table I). 
In thyrocytes, pendrin immunostaining was restricted 
to the apical membrane, and neither intracellular nor 
intraluminal staining was observed. Immunostaining was 
specific for the follicular epithelium. Stromal cells such as 
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vascular endothelial cells, lymphocytes, and macrophages 
did not show any reaction with the anti-pendrin antibody. 
Pendrin immunostaining was het erogeneous between 
follicles and thyrocytes of the same patient (Fig. 1). In the 
whole group, pendrin immunostaining percentage was 
significantly higher in nodular thyroid tissue compared 
to corresponding non-nodular thyroid tissue (64% v. 7%, 
p < 0.001) (Fig. 2A).
Quantitative measurements of pendrin mRNA by 
RT-PCR in nodular and paired normal thyroid tissue 
were performed successfully in 24 patients (Table I). No 
statistically significant difference was observed with 
respect to quantitative mRNA measurements between 
nodular and normal thyroid tissues (0.42 ± 0.42 v. 0.48  ± 
± 0.49, p = 0.657) (Fig. 2B).
Hot Thyroid Nodules (n = 18)
Pendrin immunohistochemical staining was sig-
nificantly higher in hot nodules compared to corre-
sponding normal thyroid tissue (67% v. 9 %, p < 0.001) 
Table I. Clinical and histological characteristics, immunohistochemical staining of pendrin, quantitative measurement of 
mRNA of pendrin in nodular and surrounding non-nodular thyroid tissues of the study group
Tabela I. Charakterystyka kliniczna i histologiczna, barwienie immunohistochemiczne w kierunku pendryny, pomiar ilościowy 
mRNA pendryny w guzkowej tkance tarczycy i otaczającej tkance pozaguzkowej tarczycy w badanej grupie
No Sex /age 
(yr)
TSH at the 
time of 
surgery  
[IU/mL]
Nodule 
diameter 
[mm]
Scinti- 
graphy
Histo- 
pathology
IHK positivity 
of nodules  
(%)
IHK intensity 
of nodules
IHK 
positivity of 
surrounding 
non-nodular 
tissue (%)
IHK 
intensity of 
surrounding 
non-nodular 
tissue
Pendrin 
mRNA REU 
in nodules
Pendrin 
mRNA 
REU in 
surrounding 
non-nodular 
tissue
1 F/53 0.005 45 Hot AN 90 3 0 0 0.043 0.149
2 M/48 0.007 23 Hot AN 25 2 5 1 0.007 0.043
3 F/73 0.571 51 Cold AN 80 1 10 1 0.238 0.948
4 M/37 0.462 47 Hot AN 70 1 10 1 0.447 0.455
5 F/74 0.967 45 Cold AN 50 1 0 0 0.350 0.372
6 F/54 0.071 38 Hot AN 20 1 0 0 0.022 0.293
7 M/53 0.023 49 Hot AN –* – – – 0.113 0.039
8 F/52 0.149 28 Hot AN 80 3 15 1 0.753 0.253
9 F/53 0.018 28 Hot AN 100 3 10 1 0.281 0.553
10 M/57 0.006 45 Hot AN 80 3 0 0 0.399 –**
11 F/70 2.66 34 Cold FA 100 3 0 0 0.235 0.106
12 M/60 0.022 33 Hot AN 90 3 0 0 0.245 0.145
13 M/50 0.248 43 Hot AN 50 1 10 1 0.532 0.413
14 M/40 0.499 30 Hot AN 80 2 40 1 0.133 0.195
15 F/57 0.054 25 Hot AN 30 1 0 0 0.270 0.411
16 F/72 0.008 27 Hot AN 70 3 0 0 0.292 0.321
17 F/41 1.82 23 Cold AN 10 1 0 0 0.256 0.570
18 M/54 1.15 38 Cold FA 50 2 0 0 0.079 0.305
19 F/56 0.013 45 Hot AN 100 3 10 1 –** 0.361
20 M/39 0.440 14 Hot AN 75 2 40 2 0.496 0.327
21 M/51 0.019 35 Hot AN 100 3 5 1 1.629 0.286
22 F/59 2.2 12 Cold AN 70 1 20 1 0.103 1.906
23 F/57 0.186 25 Hot AN 10 1 0 0 0.791 0.020
24 M/38 0.277 40 Cold AN 90 3 0 0 0.764 0.884
25 F/19 0.686 20 Cold AN 0 0 0 0 0.651 1.781
26 F/52 0.153 32 Hot AN 80 2 10 1 1.463 0.761
*Number 7 of the study group could not be immunostained; **For patients 10 and 19, mRNA measurements of pendrin could not be completed for technical reasons. 
REU (relative expression unit) = Target gene (pendrin)expression/ b2-microglobulin expression × 100; M — male; F  — female; MNG — Multinodular goitre; SN 
— Solitary nodule; TMNG — Toxic multinodular goitre; TA — Toxic adenoma;AN — Adenomatous goitre; FA — Follicular adenoma; NA — Not available; IHK — 
Immunohistochemistry
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(Fig. 2A). However, quantitative measurement 
of pendrin mRNA was not significantly different 
in nodular tissue compared to surrounding non-
nodular thyroid tissue (0.44 ± 0.44 v. 0.32 ± 0.22 
respectively, p = 0.326) (Fig. 2B). No significant 
correlation was observed between mRNA level and 
percent immunostaining both in non-nodular thy-
roid tissue and hot nodules (p = 0.735 and p = 0.309, 
respectively).
Cold Thyroid Nodules (n = 8)
Pendrin immunostaining was significantly higher 
in cold thyroid nodules compared to corresponding 
normal thyroid tissue (56% v. 3%, p = 0.017) (Fig. 2A). 
RT-PCR revealed significantly decreased pendrin 
mRNA levels in cold nodular thyroid tissue compared 
to normal parenchyma (0.33 ± 0.25 v. 0.86 ± 0.67, 
p = 0.036). No significant correlation was found be-
tween mRNA concentrations and percent immunos-
taining in non-nodular thyroid tissues and cold nodules 
(p = 0.098 and p = 0.740 respectively).
No statistically significant difference was found 
between hot and cold nodules with respect to quanti-
tative pendrin mRNA measurements and percent im-
munostaining (p = 0.710 and p = 0.440 respectively). 
Nor was any significant difference evident with respect 
to percent immunostaining between corresponding 
normal thyroid parenchyma of hot and cold nodules 
(p = 0.23). However, pendrin mRNA level was sig-
nificantly lower in hot nodules’ corresponding normal 
parenchyma compared to cold nodules’ corresponding 
normal tissues (p = 0.031) (Fig. 2B).
Patients with hot nodules had significantly lower 
TSH concentration at the time of operation compared 
to TSH of patients with cold nodules (0.13 ± 0.17 mIU/L 
v. 1.26 ± 0.87 mIU/L, p < 0.001).
A statistically significant correlation was observed 
between TSH and mRNA level of pendrin in normal 
thyroid parenchyma in the whole group (r = 0.397, 
p < 0.05). However, this association was lost in nodular 
thyroid tissues in the whole group (r = 0.012, p = 0.953).
Figure 2 A. Percent immunostaining of nodular and surrounding non-nodular thyroid tissues (p < 0.001). Pendrin immunohistochemical 
staining was significantly higher in hot nodules (p < 0.001) and in cold thyroid nodules ( p = 0.017) compared to in adjacent normal 
tissue. B. No statistically significant difference was observed with respect to quantitative mRNA measurements between nodular and 
normal thyroid tissues (p = 0.657). Pendrin mRNA level was significantly lower in hot nodules’ corresponding normal parenchyma 
compared to cold nodules’ corresponding normal tissues (p = 0.031)
Rycina 2 A. Procentowe barwienie immunohistochemiczne w guzkowej i pozaguzkowej tkance tarczycowej (p < 0,001). Barwienie 
immunohistochemiczne w kierunku pendryny było znamiennie bardziej nasilone w guzkach gorących (p < 0,001) i zimnych (p = 0,017) 
niż w przylegających tkankach prawidłowych. B. Nie stwierdzono statystycznie znamiennej różnicy odnośnie do pomiarów ilościowych 
mRNA pomiędzy tkanką guzkową a prawidłową tkanką pozaguzkową tarczycy (p = 0,657). Poziom mRNA pendryny by znamiennie niższy 
w prawidłowym miąższu odpowiadającym guzkom gorącym niż w prawidłowych tkankach odpowiadających guzkom zimnym (p = 0,031)
Figure 1. Immunostaining for pendrin in nodular/non-nodular 
thyroid tissues. The staining is heterogeneous and profound in 
nodules compared to surrounding tissue
Rycina 1. Barwienie immunohistochemiczne w kierunku 
pendryny w guzkowej i pozaguzkowej tkance tarczycowej. 
Poziom wybarwienia jest niejednolity i silnie wyrażony w guzku 
w porównaniu z tkanką otaczającą
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Discussion
The main finding of this study is that no significant 
difference has been found with respect to percent im-
munostaining and mRNA level of pendrin between hot 
and cold nodules. However, immunohistochemical stain-
ing of pendrin has been found to be significantly higher 
in both hot and cold nodular thyroid tissues compared 
to surrounding normal parenchyma. Cold nodules have 
had a significantly lower mRNA level of pendrin com-
pared to surrounding non-nodular thyroid parenchyma. 
Therefore post-transcriptional mechanisms could be 
associated with the increased pendrin immunostaining 
in cold thyroid nodules. In addition, no association was 
evident between TSH and quantitative measurement 
of pendrin mRNA in nodular thyroid tissue. Therefore 
different regulatory mechanisms, other than TSH, could 
be involved in pendrin expression in thyroid nodules 
and there is no association between the level of pendrin 
expression and function of the nodule.
Studies involving pendrin expression pattern in 
normal and nodular or differentiated cancer tissues of 
thyroid showed different results with respect to pendrin 
protein and gene expression level. It has been reported 
that pendrin mRNA expression was reduced in thyroid 
cancer compared to normal thyroid tissue [19]. Mian et 
al. [20] identified three types of follicular cells in thyroid 
tissue: NIS-negative/pendrin-negative cells, NIS-positive/
pendrin-positive cells, and NIS-negative/pendrin-positive 
cells. They suggested that the first two types of cells were 
resting and active cells respectively, but the functional 
status of the third type of cells was not clear.
A dissociation between pendrin immunohisto-
chemical staining and mRNA expression level has 
also been previously observed [15]. Bidart et al. [10] 
indicated that in hyperfunctioning adenomas, pen-
drin mRNA level did not differ from normal tissue but 
strong immunohistochemical staining was observed. 
In hypofunctional adenomas, although mRNA level of 
pendrin was not different from normal thyroid tissue, 
pendrin immunostaining was reported to be highly 
variable. It has been shown that retention of pendrin 
in the endoplasmic reticulum is a major mechanism for 
Pendred Syndrome, leading to endoplasmic reticulum 
retention and defective plasma membrane targeting [15, 
17]. Shepshelovich et al. [21] demonstrated that pendrin 
is a slow-folding protein. When it is overexpressed, it 
shows a propensity to form aggregates, therefore be-
ing unable to reach the apical membrane and function 
properly. Shepshelovich’s observation may indicate that 
in situations where pendrin expression is increased, 
slow folding is responsible for dissociation between 
functional protein and gene expression level. This could 
be an explanation for the dissociation between immuno-
histochemistry and quantitative mRNA concentrations 
in some studies. 
Russo et al. [22] investigated both pendrin and NIS 
expression in nodular and normal thyroid tissues of the 
same patients by Western blot analysis. They found that 
in cold nodules from patients with MNG and detectable 
TSH levels, pendrin protein by Western blot was found 
to be decreased compared to normal tissue. However, 
pendrin protein levels were slightly increased in hot 
and cold nodules of toxic MNG. 
In our study, although MNG and toxic MNG pa-
tients were evaluated together, no significant differ-
ence was found between hot and cold nodules with 
respect to mRNA level and percent immunostaining 
of pendrin. In surrounding normal thyroid tissue of 
hot nodules, pendrin mRNA concentrations were de-
creased compared to surrounding normal thyroid tissue 
of cold nodules. This observation could be explained 
by decreased TSH concentrations in our patients with 
hot nodules, since, in our study, a significant association 
has been observed between TSH and mRNA level of 
pendrin only in non-nodular thyroid tissue.
In the present study, we did not detect a significant 
association between pendrin mRNA level and TSH con-
centrations in nodules. Although pendrin expression is 
greatly influenced by TSH, some in vitro studies have 
indicated that TSH could not have a role in pendrin 
expression [6, 11]. Bruno et al. [23] also indicated that al-
though reduction of TSH stimulation caused decreases 
in NIS, apical iodide transporter gene expression in 
normal thyroid tissues by RT-PCR, no significant effect 
was observed on pendrin. Both in hot and cold nodules, 
different mechanisms other than TSH could be respon-
sible for increased pendrin immunohistochemical stain-
ing, although mRNA concentrations were decreased in 
cold nodules compared to surrounding parenchyma. It 
should be mentioned that immunohistochemistry could 
not reflect the quantitative measurements of protein 
content, therefore our suggestion should be supported 
by Western blot determination. 
Krause et al. [24] showed increased expression of 
proteins involved in cell proliferation, thyroglobulin 
processing and hydrogen peroxide detoxifying system in 
cold nodules compared to surrounding normal thyroid 
parenchyma. This observation has been explained by 
a compensatory increase in these proteins in a cold nodule 
with decreased iodine uptake and decreased expression of 
NIS. In Krause’s study [24], pendrin expression was weak 
and no difference was observed between cold nodules 
and surrounding parenchyma. In our study, the observed 
increase in immunohistochemical staining of pendrin 
compared to surrounding parenchyma in cold nodules 
could be explained by a compensatory mechanism for 
intranodular iodine deficiency. 
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The limitations of this study are that we could not 
measure pendrin protein quantitatively in tissues. It is well 
known that immunostaining is not a surrogate marker for 
quantitative measurement of protein expression.
Conclusions
Our study demonstrates that there is no significant 
difference with respect to pendrin mRNA level 
between hot and cold thyroid nodules. TSH and 
pendrin mRNA level showed a significant positive 
association in non-nodular thyroid tissue. Therefore 
we suggest that expression of pendrin could not be 
influenced by TSH in thyroid nodules, and that the 
expression level of pendrin seems not to have an ef-
fect on nodule function.
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